Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01722045 · ClinicalTrials.gov registry record · Phase 4
Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)
A Phase 4 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 154
- Enrollment target
NCT01722045 is a Phase 4 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 154 participants.
The verdict
NCT01722045, a Phase 4 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 154 participants
- Enrollment target
Study Summary
This is a phase 4, open-label, single arm, multicenter, clinical study in patients with neovascular AMD designed to evaluate the efficacy and safety of Intravitreal Aflibercept Injection (IAI) administered over 2 years , and to provide clinical information from the first year in the trial evaluating the adverse effects, if any, on the corneal endothelium following administration of IAI.
Interventions
- DRUG Intravitreal Aflibercept Injection (IAI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2012-11 |
| Est. Completion | 2015-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01722045
The ClinicalTrials.gov registry entry for NCT01722045 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intravitreal Aflibercept Injection (IAI) is the first listed.
NCT01722045 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01722045 about?
NCT01722045 is a clinical study titled "Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)". This is a phase 4, open-label, single arm, multicenter, clinical study in patients with neovascular AMD designed to evaluate the efficacy and safety of Intravitreal Aflibercept Injection (IAI) administered over 2 years , and to provide clinical information from the first year in the trial evaluating...
What is the current status of trial NCT01722045?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 154 participants. The study started on 2012-11. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01722045?
The interventions under investigation include: Intravitreal Aflibercept Injection (IAI) (DRUG).
Who is sponsoring clinical trial NCT01722045?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.